A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

Also called NCT02413398

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 321 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02413398
Other papers using this trial's data
  • Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study Diabetes, obesity & metabolism, 2018-11 DOI, PubMed 29888547, PMC6175614 PubMed links an erratum for this paper. Erratum: PMID 30516008 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Czechia, Italy, Poland, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02413398. Randomized; double masking; primary purpose treatment. Start 2015-06-15 (actual); primary completion 2017-11-07 (actual). Results posted on 2018-10-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
Acronym
DERIVE
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dapagliflozin 10 mg
Intervention (Drug)
Matching Placebo for Dapagliflozin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02413398
Content hash
0aa0e0b5eaac9f166230d40b99c1b76d9189d502ca7f6033adf65e510e68386d